Author(s):
Kajal Pansare, Ganesh Sonawane, Vijayraj Sonawane, Chandrashekhar Patil, Deepak Sonawane, Sunil Mahajan, Yogesh Ahire, Vinod Bairagi
Email(s):
kajalgsonawane@gmail.com
DOI:
10.52711/2321-5836.2025.00035 
Address:
Kajal Pansare1*, Ganesh Sonawane1, Vijayraj Sonawane1, Chandrashekhar Patil2, Deepak Sonawane3, Sunil Mahajan3, Yogesh Ahire4, Vinod Bairagi5
1Assistant Professor, Divine College of Pharmacy, Satana, Dist. Nashik - 423301, India.
2Associate Professor, Divine College of Pharmacy, Satana, Dist. Nashik - 423301, India.
3Professor, Divine College of Pharmacy, Satana, Dist. Nashik - 423301, India.
4Associate Professor, KBHSS Trust’s Institute of Pharmacy, Malegaon, Dist. Nashik - 423105, India.
5Professor, KBHSS Trust’s Institute of Pharmacy, Malegaon, Dist. Nashik - 423105, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 3,
Year - 2025
ABSTRACT:
The evolution of insulin pens from simple mechanical devices to sophisticated smart systems has significantly transformed diabetes management. Modern smart insulin pens integrate digital technologies such as Bluetooth connectivity, dose tracking, and continuous glucose monitoring (CGM) interoperability, improving adherence, glycemic control, and patient empowerment. These innovations offer tangible clinical benefits, enhancing quality of life and self-management for individuals with diabetes. However, challenges such as cost, limited accessibility, data privacy concerns, device compatibility, and digital literacy barriers persist. Regulatory pathways, including FDA and EMA approvals, and varying reimbursement policies, influence the adoption landscape globally. Future directions focus on the integration of artificial intelligence (AI) for dosing guidance, the development of semi-automated delivery systems, personalized medicine approaches, and device miniaturization. Overall, smart insulin pens represent a critical advancement toward more personalized, connected, and patient-centered diabetes care.
Cite this article:
Kajal Pansare, Ganesh Sonawane, Vijayraj Sonawane, Chandrashekhar Patil, Deepak Sonawane, Sunil Mahajan, Yogesh Ahire, Vinod Bairagi. Insulin Pens 2.0: Innovations, Challenges, and Patient-Centered Perspectives. Research Journal of Pharmacology and Pharmacodynamics.2025;17(3):213-9. doi: 10.52711/2321-5836.2025.00035
Cite(Electronic):
Kajal Pansare, Ganesh Sonawane, Vijayraj Sonawane, Chandrashekhar Patil, Deepak Sonawane, Sunil Mahajan, Yogesh Ahire, Vinod Bairagi. Insulin Pens 2.0: Innovations, Challenges, and Patient-Centered Perspectives. Research Journal of Pharmacology and Pharmacodynamics.2025;17(3):213-9. doi: 10.52711/2321-5836.2025.00035 Available on: https://rjppd.org/AbstractView.aspx?PID=2025-17-3-10
REFERENCES:
1. Bliss M. The Discovery of Insulin. University of Chicago Press; 2007.
2. Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL. Insulin injection technique: Recommendations for best practice. Mayo Clin Proc. 2015; 90(9): 1231–1255.
3. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med. 2003; 20(11):886–898.
4. Adolfsson P, Hartvig NV, Kaas A, Møller JB. Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen. Diabetes Technol Ther. 2020; 22(10):709–718.
5. Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): A multicentre, randomized, crossover trial. Lancet. 2021; 397(10270): 208–219.
6. Owens DR, Zinman B, Bolli GB. Insulin glargine: A review of its therapeutic efficacy in the treatment of diabetes mellitus. Drugs. 2001; 61(11): 1599–1628.
7. Heinemann L. Reusable insulin pens and disposable insulin pens: Past, present and future. J Diabetes Sci Technol. 2008;2(5):826–828.
8. Niskanen L, Veves A, Frier BM. The future of insulin delivery: Innovation, simplification, and outcomes. Diabetes Metab Res Rev. 2010;26(2):108–114.
9. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia with insulin analogs. Diabetes Care. 1997; 20(1):77–84.
10. Adolfsson P, Hartvig NV, Kaas A, Møller JB. Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen. Diabetes Technol Ther. 2020; 22(10):709–718.
11. Novo Nordisk. Digital Health: Smart insulin pens and connected diabetes care. 2021. [Available at: https://www.novonordisk.com]
12. Sanofi. AllStar Pro®: Technical specifications and user guide. 2020.
13. Medtronic. InPen™ Smart Insulin Pen: Product Overview. 2021.
14. Medtronic. InPen™ Smart Insulin Pen: Product Overview. 2021.
15. Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): A multicentre, randomized, crossover trial. Lancet. 2021; 397(10270): 208–219.
16. Novo Nordisk. NovoPen® 6 and NovoPen Echo® Plus: Connected devices for insulin tracking. 2021. [Available from: https://www.novonordisk.com]
17. Bigfoot Biomedical. Bigfoot Unity™ Diabetes Management System. 2022. [Available from: https://www.bigfootbiomedical.com]
18. Heinemann L. Insulin pen use: Achievements and limitations. J Diabetes Sci Technol. 2008; 2(5): 830–838.
19. Bashi N, Karunanithi M, Fatehi F, Ding H, Walters D. Remote monitoring of patients with heart failure: An overview of systematic reviews. J Med Internet Res. 2017; 19(1): e18.
20. Adolfsson P, Hartvig NV, Kaas A, Møller JB. Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen. Diabetes Technol Ther. 2020; 22(10): 709–718.
21. Kordonouri O, Hartmann R, Pankowska E, et al. The benefit of dose memory and other smart features in insulin pens. J Diabetes Sci Technol. 2017; 11(3): 567–573.
22. Schmidt S, Meldgaard M, Serifovski N, et al. Smart insulin pens improve glycemic control in people with type 1 diabetes. Diabetes Care. 2021; 44(9):e180–e182.
23. Polonsky WH, Fisher L, Hessler D, Edelman SV. Patient perspectives on self-monitoring of blood glucose: The meaning of success. Diabetes Educ. 2011; 37(4): 501–508.
24. Al Hayek AA, Robert AA, Al Dawish MA. Evaluation of insulin injection technique among patients with diabetes mellitus. Diabetes Ther. 2020; 11(6): 1227–1235.
25. Stuckey HL, Peyrot M, Curran M, et al. Personal accounts of the negative and positive impact of diabetes on quality of life: A patient survey. Health Qual Life Outcomes. 2014; 12:104.
26. Nørgaard K, Scaramuzza A, Bratina N, et al. Data sharing from smart insulin pens improves communication and treatment satisfaction. Diabetes Technol Ther. 2022; 24(2): 111–118.
27. Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: A global perspective. Lancet Diabetes Endocrinol. 2016; 4(3):275–285.
28. Atun R, Davies JI, Gale EA, et al. Diabetes in sub-Saharan Africa: From clinical care to health policy. Lancet Diabetes Endocrinol. 2017;5(8):622–667.
29. Nebeker C, Torous J, Bartlett Ellis RJ. Building the case for actionable ethics in digital health research supported by artificial intelligence. BMC Med. 2019;17(1):137.
30. Meingast M, Roosta T, Sastry S. Security and privacy issues with health care information technology. Conf Proc IEEE Eng Med Biol Soc. 2006; 1:5453–5458.
31. Heinemann L, Fleming GA, Petrie JR, et al. Insulin pens and new injection technologies: Delivery options for insulin therapy. Diabetes Technol Ther. 2015;17(9):654–662.
32. Rahi M, Rahman MM, Latif ZA. Knowledge and barriers to diabetes technology use in resource-constrained settings. J Diabetes Sci Technol. 2020;14(2):333–340.
33. U.S. Food and Drug Administration (FDA). Premarket Notification 510(k). 2021. Available from: https://www.fda.gov/medical-devices
34. European Commission. Medical Devices Regulation (EU) 2017/745. 2021. Available from: https://health.ec.europa.eu
35. American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S1–S291.
36. Heinemann L, Hompesch M, Pickup JC. Insulin pump risks and benefits: A clinical appraisal of pump safety standards, adverse event reporting, and research needs. J Diabetes Sci Technol. 2015; 9(5):1143–1152.
37. Grand View Research. Insulin Pen Market Size, Share & Trends Analysis Report, 2023–2030. 2023. Available from: https://www.grandviewresearch.com
38. IQVIA Institute. Advancing Diabetes Outcomes Through Technology. 2022. Available from: https://www.iqvia.com
39. Medtronic Newsroom. Medtronic acquires Companion Medical, maker of the InPen smart insulin pen. 2020. Available from: https://news.medtronic.com
40. Cappon G, Vettoretti M, Sparacino G, Facchinetti A. A neural-network-based approach to personalize insulin bolus calculation using CGM data. IEEE J Biomed Health Inform. 2019; 23(2): 874–881.
41. O'Connor A, Livingstone SJ, Colhoun HM, et al. big data and artificial intelligence in diabetes care: Opportunities and challenges. Diabetologia. 2021; 64(1): 57–67.
42. Boughton CK, Hovorka R. Advances in artificial pancreas systems. Sci Transl Med. 2019; 11(507): eaaw4949.
43. Maruthur NM, Gribble MO, Bennett WL, et al. Personalized diabetes management: Moving from evidence-based medicine to precision health. Lancet Diabetes Endocrinol. 2021; 9(3):170–180.
44. Zaharieva DP, Arroyo JS, Marathe PH. Personalized insulin therapy: Closing the loop between prediction and action. Diabetes Obes Metab. 2020; 22(Suppl 1):28–36.
45. Peters AL, Ahmann AJ, Battelino T, et al. Advances in technology for diabetes care: Closing the loop from hospital to home. J Diabetes Sci Technol. 2020; 14(4):783–792.